ASTRAZENECA PHARMACEUTICALS recalls Fasenra (benralizumab) Injection
- Published
- 22 Oct 2025
- Units affected
- 916 pre-filled syringes
- Agency
- FDA
- Country
- United States
The hazard
Lack of Assurance of Sterility:
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30
- Brand / company
- ASTRAZENECA PHARMACEUTICALS
- Codes / lots
- Lot YJ0152, Expiry: 01/31/2028.
- Distribution
- Nationwide in the U.S
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 22 Oct 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.